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Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart
failure patients is characterized by a reduction in life expectancy, a progressive decline in health-related quality of life and functional status,
as well as a high risk of hospitalization. New approaches are needed to address the unmet medical needs of this patient population. The
European Medicines Agency (EMA) is undertaking a revision of its Guideline on Clinical Investigation of Medicinal Products for the Treatment
of Chronic Heart Failure. The draft version of the Guideline was released for public consultation in January 2016. The Cardiovascular Round
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Table of the European Society of Cardiology (ESC), in partnership with the Heart Failure Association of the ESC,
convened a dedicated two-day workshop to discuss three main topic areas of major interest in the field and addressed
in this draft EMA guideline: (i) assessment of efficacy (i.e. endpoint selection and statistical analysis); (ii) clinical
trial design (i.e. issues pertaining to patient population, optimal medical therapy, run-in period); and (iii) research
approaches for testing novel therapeutic principles (i.e. cell therapy). This paper summarizes the key outputs from
the workshop, reviews areas of expert consensus, and identifies gaps that require further research or discussion.
Collaboration between regulators, industry, clinical trialists, cardiologists, health technology assessment bodies,
payers, and patient organizations is critical to address the ongoing challenge of heart failure and to ensure the
development and market access of new therapeutics in a scientifically robust, practical and safe way.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Chronic heart failure is a prevalent condition affecting more
than 10–12% of people over 60 years of age in developed
countries.1,2 Application of evidence-based therapy prolongs sur-
vival and reduces heart failure hospitalizations in patients with
reduced ejection fraction (HFrEF), but not in those with pre-
served ejection fraction (HFpEF). Heart failure remains a progres-
sive condition characterized by frequent hospitalizations, functional
decline, impaired quality of life, and ultimately death. Cardiovascu-
lar mortality approached 30% at 3.5 years in an optimally treated
chronic heart failure population enrolled in a recent clinical trial.3
However, it may be higher in routine practice outside of closely
monitored tertiary settings.4,5
The persistent morbidity and poor long-term survival associated
with heart failure underscores the continued need for therapeutic
innovations that slow or reverse progression and improve out-
comes for these patients. However, concerns have been raised that
investment in development of heart failure therapeutics is declin-
ing for many reasons.6,7 Regulatory requirements are perceived by
some stakeholders as one major barrier to therapeutic develop-
ment in heart failure because large and lengthy trials are necessary
before marketing authorization to demonstrate evidence of a treat-
ment effect on mortality and morbidity endpoints and to provide
assurance of safety even when mortality and morbidity are not pri-
mary targets of therapy.7 The quest for safety has been advocated,
mainly by regulators, after the withdrawal of drugs (e.g. flosequinan,
ibopamine, and milrinone) that were shown to be associated with
unfavourable long-term prognosis.8–10 However, it must be high-
lighted that at the time of the original approvals, warning signs
as regards safety were present in the small studies that suggested
benefit. In addition, the feasibility and relevance of clinical trials in
heart failure are affected by shifts in heart failure practice that have
occurred over time (e.g. trends in hospitalization patterns, location
of care delivery).
In recognition of these concerns and the changing heart fail-
ure landscape, the European Medicines Agency (EMA) is under-
taking a revision of its Guideline on Clinical Investigation of
Medicinal Products for the Treatment of Chronic Heart Failure
(EMA/CHMP/392958/2015). The EMA released a draft for public
consultation in January 2016.11 The Cardiovascular Round Table ..
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. (CRT) of the European Society of Cardiology (ESC) is a strategic
forum for high-level dialogues between ESC leadership, academia,
and industry to identify and discuss key strategic issues for the
future of cardiovascular health in Europe. In partnership with the
Heart Failure Association (HFA) of the ESC, and with involve-
ment of representatives from EMA and members of other national
Health Authorities in the European Union, the CRT convened a
dedicated two-day workshop to provide feedback on three main
topic areas addressed in the EMA guidance: (i) assessment of effi-
cacy (i.e. endpoint selection and analytical methods); (ii) clinical
trial design (i.e. issues pertaining to patient population, optimal
medical therapy, run-in period); and (iii) research approaches for
novel therapeutic principles (i.e. cell therapy). Although the scope
of heart failure clinical research expands beyond these three topics,
these were the focus areas for the workshop and the subjects of
this manuscript. This paper summarizes the key outputs from the
workshop, reviews areas of expert consensus, and identifies gaps
that need further research or discussion (Table 1).
Assessment of efficacy
Morbidity and mortality outcomes
A composite endpoint that includes death (all-cause or cardio-
vascular) and hospitalization (usually owing to heart failure) is
an accepted standard efficacy measure for chronic heart failure
trials.12 Composite endpoints have become more widely used in
the past 15 years because they reflect both survival and burden
of morbidity (i.e. reflected by hospitalization), and standard com-
posites are more feasible than a single endpoint because event
rates are higher, which can reduce the sample size and increase
power.13 For efficacy, cause-specific mortality (i.e. cardiovascular)
has been included in the composite primary endpoint in preference
to all-cause mortality in recent heart failure trials.3,14,15 Cardio-
vascular death reflects the target of treatments for heart failure,
whereas non-cardiovascular deaths are unlikely to be influenced
by heart failure therapies, even though other competing risks as a
potential source of bias should be considered when drugs improve
cardiovascular death. The Candesartan in Heart Failure Assess-
ment of Reduction in Mortality and Morbidity (CHARM) trial illus-
trates this point. The hazard ratio (HR) for candesartan vs. placebo
© 2017 The Authors
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Table 1 Workshop summary on viewpoints related to changes in the European Medicines Agency guidelines
Topic Comment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Efficacy assessments
Morbidity and
mortality outcomes
Cardiovascular mortality is usually preferred to all-cause mortality for evaluating efficacy in chronic heart
failure trials
All-cause mortality should still be assessed (with adequate power to rule out an increase) to evaluate safety
and potential off-target effects on non-cardiovascular death
Composite
endpoints
Composite endpoints should comprise only the most clinically relevant components to avoid
overestimation of treatment effects, maintain focus on the most clinically relevant endpoints, and
minimize noise related to non-response
Outpatient
management of
worsening heart
failure
The inclusion of outpatient treatment for worsening heart failure in composite primary endpoints may be
considered given the frequency of these events, their prognostic importance, evolution in heart failure
care, and the global nature of modern trials
Functional
endpoints and
quality of life
Functional capacity, symptoms, or other patient-reported outcome endpoints may be valid primary efficacy
endpoints under certain circumstances when the approach is justified by a potential benefit to public
health that outweighs the potential risk of incomplete (i.e. ongoing collection of) morbidity and mortality
data. These endpoints are most suitable as secondary or supportive endpoints to reflect the patient’s and
physician’s additional treatment goals
Analytical methods
Repeat
hospitalizations
Repeat hospital admissions are clinically meaningful to physicians and patients, can help to establish
treatment effect, and may increase the power of a study if the treatment effect is consistent among first
and repeat events
The negative binomial, Andersen–Gill, and joint-frailty model are appropriate methodologies for analysis of
repeat hospitalizations
Regulatory advice on proposed approaches is strongly recommended before initiating a heart failure trial
that is intended to support product registration and labelling, and sensitivity analyses should be planned
to evaluate the robustness of the findings
Clinical trial design
Patient population The target population enrolled in a pivotal trial should be easily identifiable and generally representative of
the intended population post-approval
If an enrichment approach is applied in a clinical study intended to support product registration, justification
that the extrapolation to use in lower-risk patients is likely to be required by regulators when a broader
indication is claimed. Approved labelling may need to reflect some of the eligibility criteria used in a
clinical trial to identify patients with the condition who have the highest likelihood of therapeutic
response. This will also depend on the risks. Conversely, the label should not reflect enrolment criteria
used solely for the purpose of enriching or homogenizing the risk of the population (e.g. BNP or
NT-proBNP above a threshold level, previous hospitalization owing to heart failure), unless the criteria
excluded a large proportion of potential patients
Optimal medical
therapy
Clinical trials should be conducted against a background of optimal evidence-based care in accordance with
treatment practice guidelines
Efforts should be made to minimize imbalances in the use of standard of care between groups, and lower
than expected use of evidence-based therapies will need to be justified to health authorities
Run-in period Consideration should be given to the impact on external validity and whether specific labelling is needed
Novel therapies Evidentiary requirements for cell-based or other novel therapies should be conceptually similar to other
therapies
Longer-term safety assessments (e.g. 5–10 years beyond original licensing) may be necessary to rule out
adverse effects
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide.
on cardiovascular mortality was 0.88 [95% confidence interval (CI)
0.79–0.97, P= 0.012), whereas no statistically significant effect on
non-cardiovascular mortality was observed (P= 0.45).16 Candesar-
tan’s lack of effect on non-cardiovascular mortality diluted the
treatment effect of candesartan on all-cause mortality (HR 0.91,
95% CI 0.83–1.00, P= 0.055).16 In contrast to all-cause mortality, ..
..
..
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..
..
..
. cardiovascular death may often require adjudication by a commit-
tee. Duration of follow-up is also an important consideration, as
most deaths in a trial with relatively short follow-up will be from
cardiovascular causes. In the draft EMA Guideline,11 it was pro-
posed that overall mortality is the preferred endpoint. However,
cardiovascular mortality, alone or as a composite endpoint, can
© 2017 The Authors
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also be considered as the primary mortality endpoint provided
that all-cause mortality is assessed as a secondary endpoint. The
majority of workshop participants suggested that cardiovascular
(and thus cause-specific) mortality may be preferred to all-cause
mortality for evaluating efficacy in chronic heart failure trials: any
effect on all-cause mortality is likely to be driven by cardiovascular
death in the heart failure population, and it is implausible that a
heart failure therapy would affect all components of all-cause mor-
tality. All-cause mortality should still be assessed (with adequate
power to rule out an increase) to evaluate safety and potential
off-target effects on non-cardiovascular death.
Composite endpoints in heart failure trials have been reviewed
in detail previously.12,17 It is outside the scope of this manuscript to
consider all the strengths and limitations of composite endpoints,
except to emphasize the importance of selecting appropriate com-
ponents. The draft EMA document11 stated that composite and
hierarchically ordered endpoints can be applied to chronic heart
failure studies, provided that mortality (overall or cardiovascular)
and hospitalization for heart failure are the first two hierarchi-
cal endpoints, respectively. The relevance of the components of
a composite endpoint varies with the mortality rate of the pop-
ulation under study. Combining mortality with many other (less
serious) time-to-event components might (but not necessarily will)
result in an overestimation of the treatment effect (see below)
and decrease the clinical importance of the results if the effect is
driven by the non-mortality components. Conversely, adding multi-
ple components may effectively increase the event rate, but if those
components are unresponsive to the treatment, then the treat-
ment effect may be muted by the ‘noise’ of non-response. Thus,
when used, composite endpoints should comprise only the most
clinically relevant components.12,17
Outpatient management of worsening
heart failure as an endpoint
Patients with worsening heart failure are increasingly being man-
aged in non-hospitalized settings (e.g. emergency departments,
specialized clinics, observation units, hospital-at-home services),
which is among other reasons, motivated by an effort to con-
tain healthcare costs.18–20 The draft EMA Guideline11 addressed
this trend by proposing that events of worsening of heart fail-
ure without hospitalization may be used as an additional endpoint.
Modern heart failure clinics have developed capabilities to monitor
and provide treatments in the outpatient setting that were pre-
viously available only to inpatients. As a result of these advances
and regional differences in heart failure treatment practices, the
location of where heart failure events are managed has become
less relevant than the characteristics of the worsening heart failure
event itself.
Until recently, worsening heart failure in the outpatient setting
has not been considered a primary event in many trials because
of concerns that these events might be less severe than those
requiring hospitalization, or that patients who can be managed
as outpatients differ from those who are hospitalized. Impor-
tantly, worsening heart failure that requires outpatient manage-
ment portends a poor prognosis similar to that of hospitalization ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. events.21–23 In the Prospective Comparison of ARNI (angiotensin
receptor–neprilysin inhibitor) with angiotensin-converting enzyme
inhibitor (ACEI) to Determine Impact on Global Mortality and
Morbidity in Heart Failure Trial (PARADIGM-HF), the risk of
all-cause mortality was similar among patients whose first event
was a heart failure hospitalization (HR 6.1, 95% CI 5.4–6.8),
emergency department visit for heart failure (HR 4.5, 95% CI
3.0–6.7), or intensification of heart failure therapy (HR 5.2, 95%
CI 4.2–6.3).22 Similar findings were reported from the Multicenter
Automatic Defibrillator Implantation with Cardiac Resynchroniza-
tion Therapy (MADIT-CRT) trial, where the mortality rates per
100 patient-years were 1.5 in patients without a primary heart fail-
ure event, 15.9 in patients with an outpatient heart failure event,
and 18.5 in patients with an inpatient heart failure event.21
One risk of adding more components to a composite endpoint
is that the magnitude of effect on the overall composite may be
diluted if the treatment effect is inconsistent across all components.
However, an analysis of data from the PARADIGM-HF trial showed
that the effect of sacubitril/valsartan on outpatient worsening was
similar to its effect on cardiovascular death and hospitalizations
owing to heart failure.22 Another challenge of including outpatient
heart failure events in a primary composite endpoint is that the
overall treatment effect may be dominated by less severe events,
but the increasing evidence supporting the prognostic importance
of outpatient worsening provides a rationale for its inclusion.22
Worsening heart failure managed in the outpatient setting should
be rigorously defined, well documented and adjudicated irrespec-
tive of whether it is a component of a primary composite endpoint
or not.24 A variety of definitions for non-hospitalized worsening
heart failure have been used in clinical trials12 and generally have
required outpatient or emergency department administration of
intravenous therapy (i.e. diuretics, vasodilators, or inotropes) for
a specific duration (e.g. ≥4 h) or outpatient intensification of heart
failure therapy [e.g. sustained, (≥1month) increase in oral diuretic
dose, or new drug therapy for heart failure).22 Inclusion of events
based on admission to emergency department or urgent care cen-
tre in the primary endpoint could be acceptable provided that
they are strictly defined (i.e. elevated natriuretic peptides, need
of intravenous diuretics, and uptitration of therapy) and centrally
adjudicated, and that it can convincingly be shown that the subpop-
ulation of heart failure patients admitted to emergency department
or urgent care centres is similar regarding disease severity and out-
come to patients admitted to hospital, thus providing reassurance
that there is no difference in the type or severity of event identified.
Given the frequency of these events, their prognostic importance,
the evolution in heart failure care, and the global nature of modern
trials, the inclusion of outpatient treatment for worsening heart
failure in composite primary endpoints may be considered, but its
role needs further justification as might be supplied from its use in
future clinical trials.
Functional and quality of life endpoints
The ability of patients to undertake normal daily activities and to
enjoy a reasonable quality of life has become ever more relevant as
patients survive longer with heart failure. In addition to a reduction
© 2017 The Authors
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in life expectancy, chronic heart failure is characterized by repeat
hospitalizations, often debilitating symptoms and impaired quality
of life, and progressive functional decline. Heart failure patients’
complaints generally focus on poorly controlled symptoms and/or
functional impairment, which to date has not been the primary
objective for the development of new drugs in heart failure. Few
studies have robustly evaluated effects of treatment on these
aspects of the heart failure patient’s experience.
A composite endpoint reflecting morbidity and mortality pro-
vides the most robust assessment of efficacy and safety for a pivotal
trial in chronic heart failure. Functional capacity, symptoms, or
other patient-reported outcome endpoints may be valid primary
efficacy endpoints under certain circumstances when the approach
is justified by a potential benefit to public health that outweighs the
potential risk of incomplete (i.e. ongoing collection of) morbid-
ity and mortality data. However, for most studies, these endpoints
would be mostly accepted as secondary or supportive endpoints
to reflect the patient’s and physician’s additional treatment goals.
The authors agree that heart failure patients need therapies that
affect all aspects of disease burden and the patient’s journey, and
thus different treatment goals may be relevant for different stages
of the syndrome.25 This is recognized in the draft EMA Guideline
which states that exercise-testing objectively evaluates functional
capacity in patients with chronic heart failure and may be relevant
to measure as a secondary endpoint under certain conditions (e.g.
patients with HFpEF).11 A primary endpoint measuring treatment
effect on functional capacity, symptoms, or other patient-reported
outcome endpoints may only be appropriate for use in a pivotal
heart failure trial in selected patient populations with an unmet
medical need (e.g. patients with end-stage heart failure or patients
with specific aetiologies such as hypertrophic cardiomyopathies
and amyloidosis), provided that appropriate blinding, with sham
procedures or placebo, is implemented. However, this depends
on the specific type of population, and an assessment of all-cause
mortality remains an important part of the safety evaluation to con-
firm the absence of off-target effects. Clinical trials in heart failure
should be sufficiently sized and of an appropriate duration to pro-
vide evidence of no harm at the time of registration.
The EMA’s pilot adaptive pathway programme (i.e. gradual
expansion of the target population, starting from a population with
high medical need, or progressive reduction of uncertainty after
initial authorization based on surrogate endpoints) was launched
to potentially accelerate patients’ access to medicines. It applied
primarily to treatments in areas of high medical need where it is dif-
ficult to collect data via traditional routes, and where large clinical
trials would unnecessarily expose patients who are unlikely to ben-
efit from the medicine.26 The newly launched PRIority MEdicines
(PRIME) scheme27 focuses on medicines with early clinical data that
suggest a major therapeutic advantage for patients with conditions
where there is an unmet medical need (i.e. for which no satis-
factory method of diagnosis, prevention or treatment exists, or,
even if such a method exists, the medicinal product concerned will
be of major therapeutic advantage to those affected), but these
programmes only apply to select circumstances. With regard to
excluding an increased risk of mortality, it is impractical to specify
a single safety margin that would be considered reassuring for all ..
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.. trials, as the margin might conceivably differ according to the
patient population. Consistency across all endpoints (i.e. clinical
outcome, and functional, patient-reported outcomes) should be
observed to provide supportive evidence of overall improvement.
Whether an adaptive pathway approach can be applied to address
treatment of a specific heart failure population will require early
consultation with the EMA for scientific advice.
When used as an endpoint (i.e. primary, secondary, or support-
ive), functional status may be assessed by a variety of measures (e.g.
peak oxygen consumption, 6-min walk distance, exercise treadmill,
or bicycle using heart failure suitable protocols), and each has its
strengths and limitations. Validation of the clinical relevance of the
endpoint in the target population, as has been done in other disease
states,28 is a key factor determining the acceptability of a functional
endpoint in a pivotal chronic heart failure trial. The predictive value
of these tests is valid only in patients whose exercise capacity is lim-
ited by heart failure. In patients with other co-morbidities, which
are frequent in patients with heart failure, factors such as peripheral
muscular deconditioning, arthritis, or low motivation can prema-
turely terminate the test. Widespread consensus has not been
achieved on the minimal relevant treatment effect that would need
to be demonstrated for endpoints such as 6-min walk distance or
exercise testing. Conceivably, this treatment effect might also vary
according to the specific study population. Notably, improvement
in 6-min walk distance led to the approval of drugs for the treat-
ment of primary pulmonary hypertension,29,30 followed by out-
come data after approval. Whether this model could be translated
to specific heart failure subsets is uncertain, but the outcome of
validation studies in the target population will be a key determinant.
Functional endpoints should be limited to assessments with
high reproducibility and reliability, and have protocol-specified
processes implemented to maximize the reliability of measure-
ments (e.g. repeated baseline and follow-up testing to reduce
variability).31 Procedures to minimize drop-outs, losses to
follow-up, and missing data, analytical methods to account for
death and handle missing data, and designs that reduce bias (i.e.
double blinding) are especially critical when these endpoints are
chosen for a heart failure trial.
In conclusion, combining traditional mortality/morbidity com-
posite endpoints and functional or patient-reported endpoints in
a single composite is of limited value for most studies, but this
approach might be useful as a means to increase power and reduce
sample size requirements, in situations where traditionally designed
outcome studies are not feasible because of technological or epi-
demiological limitations (e.g., paediatric heart failure). Symptoms
would usually overwhelm the entire composite, yielding data that
are difficult to interpret, and should generally not be used as a pri-
mary endpoint for pivotal chronic heart failure trials of traditional
therapies.
Analytical methods
Heart failure is a progressive syndrome characterized by repeat
hospital admissions, but traditional time-to-first event analysis only
considers the first event. Thus, all events that occur after the first
event (i.e. repeat hospitalizations or death, if it occurred after the
© 2017 The Authors
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first hospitalization) are ignored in the primary analysis,32 disre-
garding information that might be clinically meaningful to physicians
and patients in establishing the treatment effect. Inclusion of such
events may also increase a study’s power if the treatment effect is
consistent among first and repeat events.32
Substantial work has been done in recent years applying meth-
ods to analyse recurrent events to completed chronic heart failure
trial databases.33,34 These post hoc analyses showed that a sub-
stantial number of important clinical events were not included in
the primary analysis when only considering the first event; in the
CHARM-Preserved trial, the time-to-event analysis used only 53%
of all heart failure hospitalizations and 57% of all cardiovascular
deaths.33 A similar proportion of events were not included in the
time-to-event analysis of the Controlled Rosuvastatin Multinational
Trial in Heart Failure (CORONA) trial.34 However, methodologi-
cal issues need to be addressed, and recurrent event analyses must
account for the competing risk of mortality and the lack of inde-
pendence of repeat events within a given patient.32 Several different
analytical methods are available to address these issues, and each
has its strengths and limitations, although general agreement among
the methods (negative binomial, Andersen–Gill, and joint-frailty
model) has been noted.33,34 As suggested by Rogers et al.,33 the
choice of the primary analysis method depends on the desired
balance between interpretability and robustness of the analysis;
population characteristics (e.g. low or high death rates) also plays a
role. The Efficacy and Safety of LCZ696 Compared to Valsartan on
Morbidity and Mortality in Heart Failure Patients with Preserved
Ejection Fraction (PARAGON-HF) trial was designed with the pri-
mary endpoint of cumulative number of primary composite events
of cardiovascular death and total (first and recurrent) heart fail-
ure hospitalizations (http://clinicaltrials.gov, NCT01920711).35 The
Calcium Upregulation by Percutaneous Administration of Gene
Therapy in Patients with Cardiac Disease (CUPID 2) recently used
this approach with a joint frailty analysis to assess time-to-recurrent
heart hospitalizations accounting for correlated recurrent events
within patients and the correlation between recurrent and termi-
nal events.36 Consensus has not been achieved on best practice for
presenting recurrent events data, and these decisions may need to
be considered on a trial-by-trial basis. At a minimum, regulatory
advice on proposed approaches is strongly recommended before
initiating a heart failure trial that is intended to support product
registration and labelling, and sensitivity analyses should be planned
to evaluate the robustness of the findings.
Clinical trial design
Patient population
The target population enrolled in a pivotal trial should be easily
identifiable and generally representative of the intended population
post-approval. Enrichment criteria are often employed in modern
clinical trials either to: (i) define the population and ensure enrol-
ment of patients with the condition [e.g. B-type natriuretic peptide
(BNP) orN-terminal-proBNP (NT-proBNP) criteria to confirm the
diagnosis of heart failure]; (ii) ensure enrolment of a sufficiently
at-risk population to meet event rate and sample size assumptions; ..
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.. (iii) homogenize risk among enrolled patients; or (iv) select patients
where a positive benefit/risk relationship is most likely based on
the documented presence of the target mechanism of action. An
enrichment strategy designed to increase the event rate also iden-
tifies the patients with the greatest medical need.
If an enrichment approach is applied in a clinical study intended
to support product registration, justification that the extrapolation
to use in lower risk patients is likely to be required by regulators
when a broader indication is claimed. Approved labelling may
need to reflect some of the eligibility criteria used in a clinical
trial to identify patients with the condition who have the highest
likelihood of therapeutic response. This will also depend on the
risks. Conversely, the label should not reflect enrolment criteria
used solely for the purpose of enriching or homogenizing the risk
of the population (e.g. BNP or NT-proBNP above a threshold
level, before hospitalization because of heart failure), unless the
criteria excluded a large proportion of potential patients. If a
treatment effect is shown in an enriched population and the results
are applied to a lower risk population, the absolute benefit of
treatment may be less in the lower risk population, which may
also have implications for health technology assessments and payer
decisions. Broader regulatory indications allow local authorities
and downstream stakeholders to determine how the results most
appropriately apply to their populations.
Patients admitted to hospital with acute heart failure should not
be enrolled in chronic heart failure trials in the early phase of
that admission while the patient is unstable. Many interventions
may take place during a hospitalization for acute heart failure (e.g.
administration of intravenous diuretic and vasoactive therapies,
uptitration of evidence-based therapies, implantation of cardiac
devices), and these treatment measures may mask the treatment
effects of the investigational therapy. However, it may be valuable
to enrol patients hospitalized for heart failure in the hospital
setting who are stabilized and not receiving parenteral therapy to
evaluate the effect of chronic therapies that are started during the
hospitalization, at discharge, or in the early post-discharge period
(e.g. 30 days post-discharge).
Patients enrolled in ‘chronic’ heart failure trials should gener-
ally be in the ambulatory care setting and taking stable doses
of “disease-modifying” therapies (e.g., beta-blockers), although
dynamic adjustment of diuretic dosing should be permitted. Some-
times there may be a reason to wish to enroll patients early
after treatment for acute decompensation and here a pragmatic
approach may be to recruit patients after discontinuation of par-
enteral therapies but before discharge. For certain types of novel
therapies (e.g., those with a renal, diuretic, or natriuretic action)
patients might be enrolled at an earlier stage of their admission,
before decongestion has been achieved with conventional therapy.
Optimal medical therapy
Clinical trials should be conducted against a background of opti-
mal evidence-based care in accordance with treatment practice
guidelines.1 However, clinical trials should also reflect real-world
practice. Global trials are a necessity to achieve the large patient
numbers needed in modern randomized outcome trials, to allow
© 2017 The Authors
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for worldwide regulatory approval, and to assess the generaliz-
ability of treatments. Some variation in standard of care across
geographic regions is expected, particularly with cardiac devices,
because of differences in product availability, reimbursement poli-
cies, local standards of care, or other factors that affect patient
access.37 Patients enrolled within a region should be representa-
tive of local standards of care, and randomization should minimize
the impact of any differences in standard of care between groups.
Efforts should be made to minimize imbalances in the use of stan-
dard of care between groups, and lower than expected use of
evidence-based therapies will need to be justified to health author-
ities. Given the usually lengthy timeframe required for recruitment
and follow-up of randomized trials, changes in standard of care may
occur and should be allowed, but also should be documented and
justified.
Geographical differences in event rates, as well as treatment
responses, have often been observed in heart failure and other
cardiovascular clinical trials.38–42 Pre-specified analyses to evaluate
the consistency of treatment effect by geographic region are often
performed. However, it is important to recognize the limitations of
subgroup analyses,43–47 and consider the likelihood that observed
differences between subgroups could result from chance because
of multiple testing and the small number of patients, especially when
considering regional or individual country differences.
Run-in period
Some clinical trials are designed with an active treatment run-in
period to maximize the ability to retain patients on treatment
long-term by excluding patients with tolerability issues.35 Regula-
tory agencies may request a run-in period to ensure that standard
care treatments are optimally administered.3 In clinical trials where
an active treatment run-in period is used, consideration should be
given to the impact on external validity (i.e. rates of intolerance
could be higher in clinical practice as in a clinical trial the run-in
selects patients who can tolerate the drug), although it should be
noted that active treatment run-ins mimic clinical practice since
physicians routinely discontinue therapy that is not tolerated. Fur-
ther, active run-in periods in clinical trials generate important
evidence about tolerability and reasons for discontinuation that
are useful for physicians in practice. Whether specific labelling is
needed will be determined by regulators on a case-by-case basis.
Run-in periods to improve recruitment efficiency may lead to physi-
cian concerns that tolerability and efficacy data are overestimated,
which may affect uptake and acceptance of the therapy.48–50
Research approaches for novel
therapies
Novel treatment approaches to the heart failure patient, such as
cell-based, gene, and other bioactive agents, have the potential to
significantly increase myocardial performance and clinical status.
Over the past 15 years, rapid development of numerous products
and modes of administration have given rise to the conducting
of many small clinical studies early in the evolution of the field. ..
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.. Unfortunately, progress has been impeded by the lack of optimally
designed, sufficiently large studies with adequate statistical power,
uncertainty as to product classification and regulatory guidance,
and high costs compared with other therapies (often shouldered
by small companies). Perhaps most importantly, the absence of a
single first-in-class agent upon which to centre substantial early
development (unlike many novel pharmaceuticals and devices) has
led to important questions regarding the appropriateness and rele-
vance of testing these products in the traditional constructs of ran-
domized, controlled trials. The workshop acknowledged the field’s
continued promise, as well as the challenges of acquiring meaningful
data, including access to adequately trained investigators, main-
taining blinding at the site level when agent delivery increasingly
utilizes sham procedures for control groups necessitating a firewall
between interventional and clinical site personnel, and site-related
logistics for dose preparation.
Consensus was reached among participants that the evidentiary
requirements for cell-based or other novel therapies should be
conceptually similar to other therapies. Both meaningful clinical
benefit and safety need to be demonstrated to support approval.
A rationale also exists for accepting functional or patient-reported
outcome endpoints for these therapies, as patients who may
be considered as candidates are likely to be those who remain
symptomatic after optimization of other guideline-recommended
evidence-based therapies. Longer term safety assessments (e.g.
5–10 years beyond original licensing) may be necessary to rule
out adverse effects. As above, blinding of patients and/or the
assessment team is challenging but it is essential to the scientific
validity of the findings and should be implemented whenever
possible, with plans for maintaining the blind design carefully
detailed. Endpoints should be selected considering not only the
evidence required for licensing, but also for payers,51 as these
therapies are likely to be costly. An endpoint such as freedom
from death, transplant, or mechanical circulatory support might
be relevant for these therapies, but durability of the effect will be
important to assess, especially from the payer’s standpoint.
Observation of a large treatment effect could potentially support
acceleration of patient access to the therapy via, for example,
conditional approval approach or PRIME if an unmet need can be
established. While this has not been warranted based upon current
evidence, many treatments for heart failure are in development and
establishing a development pathway for advanced cell-based and
non-cellular agents is an important step.
Conclusion
Patients with chronic heart failure have a reduced life expectancy
and diminished quality of life, with high healthcare utilization.
The composite endpoint of cardiovascular mortality or hospi-
talization owing to heart failure provides a clinically meaningful
assessment of efficacy, and can be used in most pivotal trials of
chronic heart failure therapies, with adequate ascertainment of
non-cardiovascular mortality to confirm safety regarding increased
mortality. Patients with worsening heart failure will increasingly
receive care in non-hospitalized settings, and it is recognized that
© 2017 The Authors
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outpatient heart failure events may also represent valid endpoints.
The possibility of including repeat events in the primary analysis has
opened many opportunities to develop and pilot new methods for
statistical analyses that may improve the efficiency as well as the
clinical relevance of randomized heart failure trials.
A rationale exists for evaluating functional or patient-related
outcome endpoints as key secondary or supportive endpoints in
chronic heart failure trials. This recognition is a call to researchers
to generate evidence for determining minimally important differ-
ence thresholds and validating these endpoints as meaningful, not
only to improve patients’ symptoms and physical limitations, but
also as they relate to directionally similar changes in outcomes such
as death or hospital admission.
In order to address the remaining unmet medical needs in
heart failure patients, we should endeavour to refine the target
patient populations and develop novel therapies. Collaboration
among regulators, industry, clinical trialists, cardiologists, payers,
and patient organizations will be critical to ensure that scientifically
robust and practical solutions to developing new therapeutics in
this patient population are implemented.
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